AUTHORS
Carmine Deluca, BA, Marina Wanes, MS2, Michael Beyer, BS3, Shambavi Richard, MD4, Joshua Richter I, MD5, Jonathan L Kaufman, MD6, Krina Patel Jr, MD, MSc7, Hans C Lee, MD8, Sagar Lonial, MD, FACP9
AFFILIATIONS
1 PVI, PeerView Institute for Medical Education, New York, New York, United States
2 PVI, PeerView Institute for Medical Education, New York, New York, United States
3 PVI, PeerView Institute for Medical Education, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 Sarah Cannon Research Institute, Development Innovations, Nashville, Tennessee, United States
9 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
ABSTRACT
Background: The advent of CAR-T therapy has provided an effective immunotherapy option for patients with multiple myeloma (MM), but logistical and access barriers present challenges to successful administration (Ailawadha S, et al. J Clin Oncol 2026;44, 7530). Off-the-shelf immunotherapy options, including bispecific T-cell engaging antibodies (TCEs) targeting BCMA and GPRC5D, alongside BCMA targeting antibody-drug conjugates (ADCs), offer potential solutions based on ease of access, potent efficacy, and potential for rapid deployment. Although the availability of off-the-shelf therapy in earlier relapse settings offers an alternative to CAR-T (NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 5.2026), operationalizing these strategies has also proved challenging based on unique dosing and safety monitoring characteristics. We assessed US-based clinicians in order to clarify modern practice patterns and healthcare team preparedness to successfully operationalize off-the-shelf BCMA and GPRC5D therapy in MM.
Methods: Twelve virtual workshops were conducted in collaboration with a national network of oncology practices in the United States in 2025 and 2026, with sessions focused on the healthcare team’s role in integrating TCEs and ADCs into MM care alongside cellular therapy options. Four on-demand self-study online initiatives and three live in-person educational sessions held at major hematology-oncology and cell therapy congresses were also included in this analysis. 14,467 learners participated, including 5,788 hematologist-oncologists, 3,330 hematologists, and additional advanced practitioners, pharmacists, and nurses. Baseline experience, practice preparedness, and care planning capabilities were assessed via learner data, polling, and qualitative inputs. Pre- and post-assessments were analyzed to evaluate changes in clinician skills. Analyses were conducted using available responses for each assessment item; post-assessments were voluntary, resulting in varying sample sizes across questions.
Results: Clinicians demonstrated significant improvements in case-based clinical decision-making following education (P<0.05 for all comparisons). Among respondents completing each assessment, selection of off-the-shelf therapy in early-relapse case scenarios increased from 50% at baseline to 81% following education. Readiness to integrate off-the-shelf immunotherapy in later relapse scenarios increased from 37% to 78%. Skills related to step-up dosing and transition to therapeutic dosing showed the largest absolute improvement, increasing from 23% to 74%. Implementation of best practices for coordination with eye care specialists during dosing of ADC therapy improved from 53% to 81%, reflecting increased preparedness to address multidisciplinary aspects of care. Qualitative analyses of faculty-led discussions and participant dialogue suggested regional differences in implementation maturity within community practices. Discussions in Western US practices more frequently focused on optimization of sequencing strategies and long-term management, whereas Northeastern US practices emphasized infrastructure development, toxicity monitoring, staffing, and referral workflows. Across regions, co-management between academic and community centers emerged as an increasingly important strategy.
Conclusion: These findings suggest increasing clinician readiness to apply evidence supporting the integration of off-the-shelf immunotherapy in MM, including in early relapse settings, while highlighting operational challenges that vary across practice environments. Continuing educational initiatives that focus on implementation logistics, toxicity management, and academic–community collaboration may support this progress and facilitate broader adoption of off-the-shelf BCMA and non-BCMA immunotherapy options.
DISCLOSURES
Carmine Deluca, BA: No relevant conflicts of interest to declare.